The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Not Applicable

Completed

• Conditions: Diabetes Mellitus
• Interventions: Other: GLP-2 infusion; Other: Sodium-chloride; Other: GIP-infusion

• Registration Number: NCT00732602
• Lead Sponsor: University Hospital, Gentofte, Copenhagen

Brief Summary

The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Primary Completion: 2008-08
• Study First Submitted: 2008-08-11
• Study First Submitted QC: 2008-08-11
• Study First Posted: 2008-08-12
• Status Verified: 2009-02
• Last Update Submitted: 2009-02-12
• Last Update Posted: 2009-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Caucasians over 18 years with type 1 diabetes (WHO criteria)
• Arginine test without rise in plasma C-peptide
• Normal blood Hemoglobin
• Informed consent

Exclusion Criteria

• Liver disease
• Diabetic nephropathy
• Treatment with medications unpausable for 12 hours

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
B	GLP-2 infusion	GLP-2 infusion
C	Sodium-chloride	Sodium-chloride infusion
A	GIP-infusion	GIP-infusion

Primary Outcome Measures

Name	Time	Method
plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.

Trial Locations

Locations (1)

University Hospital, Gentofte; 🇩🇰 Hellerup, Capital Region, Denmark